MICALL2, MLXIPL, and MXD3 Link Serum Uric Acid to Immune Evasion and Drug Sensitivity in Prostate Cancer

Name: MICALL2, MLXIPL, and MXD3 Link Serum Uric Acid to Immune Evasion and Drug Sensitivity in Prostate Cancer
Creator: Jinhai Wu
Published: 2025-09-03T19:03:37.354Z
Keywords: Oncology

Wu, Jinhai

doi:10.17632/ydf4zt5hzb.1

MICALL2, MLXIPL, and MXD3 Link Serum Uric Acid to Immune Evasion and Drug Sensitivity in Prostate Cancer

Published: 3 September 2025| Version 1 | DOI: 10.17632/ydf4zt5hzb.1

Contributor:

Jinhai Wu

Description

MICALL2, MLXIPL, and MXD3 may promote PCa progression through metabolic–immune crosstalk and serve as potential prognostic biomarkers and predictors of therapeutic response, offering novel insights for precision treatment strategies.

MICALL2, MLXIPL, and MXD3 Link Serum Uric Acid to Immune Evasion and Drug Sensitivity in Prostate Cancer

Description

Files

Categories

Licence